Authors: POWE LK DEBOVE C ZEISSER P

Citation: Lk. Powe et al., RILUTEK GLOBAL EARLY ACCESS PROGRAM (EAP) REACHES OVER 10-PERCENT OF AMYOTROPHIC-LATERAL-SCLEROSIS (ALS) POPULATION, Neurology, 50(4), 1998, pp. 1069-1069

Authors: RIVIERE M MEININGER V ZEISSER P MUNSAT T

Citation: M. Riviere et al., AN ANALYSIS OF EXTENDED SURVIVAL IN PATIENTS WITH AMYOTROPHIC-LATERAL-SCLEROSIS TREATED WITH RILUZOLE, Archives of neurology, 55(4), 1998, pp. 526-528

Authors: GEHANNO P ZEISSER P BREMARDOURY C

Citation: P. Gehanno et al., COMPARISON OF EBASTINE WITH CETIRIZINE - RESPONSE, Annals of allergy, asthma, & immunology, 79(5), 1997, pp. 465-466

Authors: MEININGER V DIB M AUBIN F JOURDAIN G ZEISSER P

Citation: V. Meininger et al., THE RILUZOLE EARLY ACCESS PROGRAM - DESCRIPTIVE ANALYSIS OF 844 PATIENTS IN FRANCE, Journal of neurology, 244, 1997, pp. 22-25

Authors: GEHANNO P BREMARDOURY C ZEISSER P

Citation: P. Gehanno et al., COMPARISON OF EBASTINE TO CETIRIZINE IN SEASONAL ALLERGIC RHINITIS INADULTS, Annals of allergy, asthma, & immunology, 76(6), 1996, pp. 507-512